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The outbreak of the novel SARS-COV-2 and its following complications has caused an 
almost unprecedented chaos throughout the world in recent years. Although a series of 
vaccines have been proposed recently in order to reduce the risk of mortality and mor-
bidity of this disease, an ultimate and reliable cure has yet to be discovered. One of the 
major complications of Covid-19 is the outburst of a series of inflammatory responses 
in the respiratory system of the patients, which eventually causes a hypoxemic pneu-
monitis and accounts for most of the Covid-19 patients’ mortality. It is suggested that 
a group of inflammatory cytokines such as different interleukins are responsible for 
this complication, therefore drugs which can influence this system may be useful in 
reducing this exaggerated inflammatory response which is dubbed the ‘cytokine storm’. 
In this article we review potential treatment options for reducing the inflammatory re-
sponse and discuss some clinical trials and case reports related to the drugs interfering 
with responsible interleukins in order to quench the cytokine storm. 
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udates of fibrin with subsequent aggregation of proteins. 
A reactive hyperplasia of type II pneumocytes also occurs 
with accumulation of different types of white blood cells 
such as monocytes, macrophages, and other mononuclear 
cells within alveoli. [14, 15]. Covid-19 attacks the respira-
tory system via invading epithelial cells and type 2 pneu-
mocytes by attachment of the virus spike protein to the an-
giotensin converting enzyme 2 (ACE2) receptors [16]. The 
regulator gene of this receptor has shown a dose-dependent 
expression concomitant with the higher levels of SARS-
CoV-2 virus, and is upregulated by interferon regulating 
genes such as Interferon Alpha Inducible Protein (IFI) 27, 
and IFI 6 [17]. This is while SARS-COVID-2 decreases 
surface expression of ACE2 receptors [18]. ACE2 acts via 
converting Angiotensin 2 into Angiotensin 1-7, and there-
fore has a vasodilatory effect. Moreover, it has a reducing 
effect on bradykinin expression, hence with the blockade of 
ACE2 receptors, high amounts of bradykinins can stimulate 
inflammatory response [19]. 
Cytokine Storm and Its Effects on Lung Pathology
Following entrance of SARS-COV2 into the respiratory ep-
ithelial cells, the virus provokes an immune response which 
leads to the production of plentiful amounts of inflamma-
tory cytokines. Pathogenic T helper 1 (Th1) cells and in-
termediate CD14+, and CD16+ monocytes ignite a series 
of inflammatory immune responses which happen by the 
interaction between the membrane‐bound immune recep-
tors with antigens and the subsequent signaling pathways. 
This is followed by infiltration of macrophages and neutro-
phils into the epithelial cells of the lungs which provokes 
cytokine storm [12]. This happens when SARS-COV-2 
stimulates Th1 cells to produce inflammatory mediators for 
instance different kinds of interleukins (e.g., IL1 and IL6), 
granulocyte-macrophage colony stimulating factor (GM-
CSF) which stimulates CD14+, CD16+ monocytes to se-
crete massive amounts of other cytokines such as tumor ne-
crosis factor α (TNFα) [12, 20]. The release of these types 
of cytokines is associated with a series of manifestations 
such as flu like symptoms, fatigue, cardio -myopathy and 
lung injury. IL6 can cause vascular leakage which activates 
complement and coagulation pathways that could cause dif-
fuse intravascular coagulation. These clinical features are 
mostly seen in COVID-19 patients in severe condition and 
are major contributing factors to the mortality of this dis-
ease [21, 22].
Medications Effective in the Modulation of the Cytokine  
Storm
Considering the fundamental role of cytokine storm in se-
verity of the COVID-19, anti-inflammatory drugs may be 
a potential therapy for reducing morbidity and mortality of 
this disease. The time period in which the anti-inflamma-
tory drugs are used is of great importance, since there is a 
seven-day critical time between the onset of the symptoms 
and worsening of the patient’s condition towards critical 
status [21]. This type of treatment has its own disadvan-
INTRODUCTION
The beginning of 2020 was heralded by an outbreak of a 
coronavirus, severe acute respiratory syndrome corona-
virus-2 (SARS-COV-2). The current global pandemic of 
SARS-COV-2 has been spreading limitlessly throughout 
the world since December 2019. It primarily was observed 
in Wuhan city, China and to date, over 172 million con-
firmed cases and over 3 million deaths are reported by 
WHO [1]. Ever since there has been a significant effort for 
finding a treatment for this disease. Although a series of 
vaccines have been introduced among which some are FDA 
approved and are currently being injected, but a definitive 
cure is yet to be found [1, 2]. 
Various complications are attributed to this disease. Pa-
tients diagnosed with covid-19 often develop a hypoxemic 
pneumonitis with a profound inflammatory response which 
may be caused by elevated levels of inflammatory cytokines 
such as IL1 and IL6, interferon-γ inducible protein 10, and 
granulocyte-colony stimulating factor (GCSF) [3]. These 
cytokines increase the amount of cell adhesion molecules 
and vascular-endothelial growth factor (VEGF) in the lung 
and thereby increase the permeability in the lung epitheli-
al cells and decrease barrier protection, which allows viral 
propagation and infiltration of neutrophils and inflammato-
ry monocytes. These cytokines stimulate release of imma-
ture granulocytes from bone marrow which exacerbate the 
lung epithelium adherence and inflammation. This so called 
second loop in the lung leads to a series of systemic in-
flammations which culminate in what is known as cytokine 
storm syndrome [4]. This cytokine storm causes diffuse al-
veolar damage and acute respiratory distress syndrome and 
is the leading cause of mortality in the covid-19 patients 
(see below) [5]. 
A considerable amount of researches and trials have been 
carried out about Covid-19 treatment and drugs which an-
tagonize IL1 and IL6 receptors may be a promising ap-
proach for this purpose [6-10]. 
COVID-19 and Its Pathologic Respiratory Features
Corona virus is a positive-sense, single-stranded RNA virus 
which belongs to the family Coronaviridae with a genome 
size of approximately 30 kilobases. The virus encodes mul-
tiple structural and non-structural proteins. The former 
consist of: spike, envelope, membrane, and nucleocapsid 
protein, and the latter are responsible for corona virus RNA 
synthesis and processing. This is done by nonstructural 
protein (NSP) 7 to 16, which are cleavage products of two 
large replicase polyproteins translated from the coronavirus 
genome. [11]. The virus apparently triggers both humoral 
and cellular immune responses which may notoriously af-
fect respiratory system. The severe lung injury in patients 
with covid-19 results from both direct viral infection and 
immune system overreaction [12, 13]. The detrimental 
changes consist of a constellation of pathologic process-
es occurring both in macro- and microenvironment. Hya-
line membrane formation may cause vast alveolar damage 
which may be accompanied by pulmonary edema, and ex-
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tages, for instance a number of cytokines such as interleu-
kins 1, 6, 10, 12 and 17 are necessary in the process of 
virus clearance and therefore anti-interleukin drugs could 
cause some complications. Furthermore, immune sys-
tem deficiencies occurs in some patients suffering from 
COVID-19 and utilization of anti-inflammatory drugs such 
as glucocorticoids may exacerbate their situation [23]. An-
other option for COVID-19 treatment is administration of 
human immunoglobulin for intravenous use (IVIG). These 
molecules are natural antibodies with poly reactive prop-
erties with the ability to recognize and neutralize exoge-
nous antigens of viral and bacterial origin, toxins and super 
antigens, or endogenous antigens like cytokines, chemok-
ines and metalloproteases. IVIG molecules also depend on 
their Fc region interaction with the Fcγ receptors (FcγRs) 
to induce anti-inflammatory / immune-regulatory respons-
es. Since FcγRs are expressed on cells involved in natu-
ral immunity (phagocytes), adaptive immunity (T cells, B 
cells), and also on antigen presenting-cells which connect 
both types of immunities, this interaction acts as a modi-
fier for signaling through FcγRs and eventually may lead 
to strong anti-inflammatory responses [24]. Many studies 
have suggested that complement system becomes active 
during body exposure to SARS-CoV in humans and ani-
mals. It appears that a large amount of complement residues 
are dispersed throughout the bodies of patients, so finding 
a molecule with antagonistic potential against complement 
receptors could be promising in reducing the inflammatory 
response in these patients. Studies show that a humanized 
monoclonal antibody that works against complement recep-
tor, C5a could reduce SARS-CoV-induced lung injury in 
mice and monkeys, therefore drugs with this mechanism 
such as [Eculizumab] might play a functional role [25]. An-
other important factor in inflammatory response is TNFα. 
It is mainly produced by macrophages and to a lesser extent 
by monocytes and B cells. TNFα stimulates IL1 and IL6 
production and is vastly observed in the blood and tissues 
of COVID-19 patients. Therefore, anti TNFα drugs such as 
[Adalimumab] and [Infliximab] can be a logical option in 
the modulation of cytokine storm [26]. Calcitonin gene-re-
lated peptide (CGRP) is a potent vasoactive peptide and 
potential cardio-protective mediator. CGRP has also been 
found in pulmonary afferent nerve fibers and contributes 
to the vasodilation of pulmonary vasculature. Studies show 
that CGRP has an inducing effect on IL6 production; there-
fore, CGRP antagonists could have effects in treating cyto-
kine storm [27]. 
Drugs in statin group are also considered potentially effec-
tive. Statins can be effective in the modulation of lipids, 
induction of autophagy, modulation of coagulation process, 
and regulation of NLRP3 inflammasome mediated inflam-
mation. NLRP3 is a molecule belonging to NLR protein 
family and has a tripartite structure. It provokes immune 
system via activation of caspase-1 and IL1ß and IL18 [28, 
29]. In another study, it was reported that Haloperidol de-
creased rate of mortality in patients on mechanical ventila-
tion which might be due to its effect on lowering cytokine 
levels, therefore it can be potentially useful in combating the 
inflammatory response in COVID-19 [30, 31].
Role of Interleukin Antagonists in the Modulation of the 
Cytokine Storm
Several interleukins are involved in the inflammatory re-
sponse of the cytokine storm such as IL-1β, IL-2, IL-4, IL-6, 
IL-8, IL-12, IL-13, and IL-17 [32]. One of the major interleu-
kins responsible for the cytokine storm is interleukin 6 which 
is activated by leukocytes and promotes differentiation of B 
lymphocytes and secretion of acute phase proteins [33]. In-
terleukin 6 has an important role in the dendritic cell -T cell 
interaction which is crucial for the synthesis of T helper 17 
cells along with other factors such as TGF-ß and IL-23. The 
T helper 17 cells secrete interleukin 17 which is responsible 
for the apoptosis of alveolar epithelial cells and progression 
to pulmonary fibrosis which compromises normal alveolar 
architecture, alveolar-capillary gas exchange, and eventually 
normal oxygenation in the lungs leading to the respiratory 
symptoms of the disease [32]. It seems that following the 
increase of IL-6 synthesis in COVID-19 patients, the num-
ber of T helper 17 cells escalates noticeably. There are var-
ious ways to inhibit IL-17 related pathways such as direct 
inhibitors, receptor antagonists, and direct pathway blockers 
[34, 32]. To date, there are three IL‐17 blockers available: 
[Secukinumab]; an IgG 1, which directly binds to IL17A, 
[Ixekizumab]; an IgG4, which also directly binds to IL17A, 
and [Brodalumab]; an IgG 2, which binds selectively to 
IL17A receptor and inhibits its interaction with IL17A [35]. 
On the other hand, IL-6 acts through the Janus kinase-Sig-
nal Transducer and Activator of Transcription (JAK-STAT) 
signaling pathway to implement various immunological ef-
fects such as immune regulation, lymphocyte growth and se-
cretion, and oxidative stress; consequently, finding a way to 
block the JAK-STAT pathways could actually have a role in 
reducing the cytokine storm severity [36], and [Ruxolitinib] 
and [Baricitinib] are drugs with JAK/STAT inhibition poten-
cy which could be helpful in this setting [36]. 
IL-6 effect can also be restricted through IL-6 receptor an-
tagonists such as [Tocilizumab] and [Sarilumab], or by [Sil-
tuximab] which binds directly to IL6 [37]. Tocilizumab has a 
long half-life and it is not easily available in clinic, therefore 
there is still a high demand for other potentially effective 
immunomodulatory drugs [10]. IL1 also plays a noticeable 
role, for example [Anakinra], a drug with antagonistic effect 
on IL-1 receptor, is commonly used in rheumatologic con-
ditions and is of great importance in COVID-19 [38]. This 
is because IL1 is involved considerably in thrombotic com-
plications and venous thromboembolism caused by COVD-
19, and also induces the secretion of TNF which itself is a 
pro inflammatory cytokine. Both IL1 and TNF molecules are 
involved in the COVID-19 cytokine storm. When an inflam-
mation happens, thromboxane A2, which is released by IL1, 
causes platelet vascular thrombogenicity both on endothelial 
and on non-endothelial cells. IL-1 is the most important im-
mune molecule in inducing fever, since it has a role in the me-
tabolism of arachidonic acid which is released from vascular 
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endothelial organs of the hypothalamus which function as a 
center for temperature control of the body. [Canakinumab] 
is another antagonist in this group which is a human mono-
clonal antibody against IL-1β and is used in the treatment 
of inflammatory diseases such as Familial Mediterranean 
Fever, and can have possible effects on COVID-19 related 
inflammatory response [39]. Hence, blockade or synthesis 
inhibition of IL-1 blocks all the pathological events, which 
can lead to death of the COVID-19 patient [40, 41]. 
Clinical Trials and Case Reports
Tocilizumab
Several studies are performed concerning the effectiveness 
of interleukin antagonists, among them Tocilizumab and 
Anakinra are the most worked on.
A clinical trial was performed among 255 COVID-19 pa-
tients. The patients were randomly given Sarilumab or To-
cilizumab, an IL6 antagonist. Patients were divided into two 
groups: those requiring ≤45% fraction of inspired oxygen 
(FiO2) (termed stage IIB, 106 patients) and those requiring 
>45% FiO2 (termed stage III, 149 patients). Only one pa-
tient needed ventilation in group IIB, while 16 patients of 
group III required mechanical ventilation. Patients treated 
in stage IIB had lower mortality than those treated in stage 
III and also had shorter length of stay (mean days of stay 
11.3 for IIB versus 15 for III). Hence, IL6 receptor inhibitor 
administration prior to entering stage III, was associated 
with improved COVID-19 outcomes [42].
Tocilizumab effects was assessed on 80 COVID-19 patients 
in a clinical trial. More than 88% of patients who were giv-
en IL-6 inhibitor did not need mechanical ventilator (MV). 
Moreover, Tocilizumab reduced the cytokine storm and in-
flammatory response in the majority of patients. This re-
duction in cytokine release appeared to be the cause of de-
crease in requiring mechanical ventilation of these patients 
and reduced the mortality and morbidity [6]. 
A comparative analysis was done on 74 recipients of To-
cilizumab and 148 controls who were treated with hydroxy-
chloroquine plus [Lopinavir/ritonavir] or [Remdesivir] as 
standard of care. In patients with severe disease, Tocilizum-
ab did not seem to have any beneficial effect, while it ex-
erted an obvious improvement in critical patients. A severe 
case was defined as the presence of respiratory distress, 
oxygen saturation in room air ≤93% at rest or P/F (arterial 
pO2 divided by the FIO2) ≤300 mmHg. A critical case was 
defined as the presence of respiratory failure which needs 
ventilation (either invasive or not), septic shock or any oth-
er organ dysfunction requiring ICU monitoring and treat-
ment. Tocilizumab use was accompanied with a better over-
all survival compared to controls, but with a longer hospital 
stay mainly due to biochemical, respiratory and infectious 
adverse events. It is recommended to use Tocilizumab cau-
tiously regarding its adverse effects, remarkable worsening 
of respiratory conditions, and bacterial infections. Short-
ly after Tocilizumab administration, the patients needed a 
transient ventilation, but they recovered. Since ventilation 
might compromise drug benefits and patients could proceed 
to critical state immediately after drug receiving, respirato-
ry monitoring after drug administration is needed [43].
In a clinical trial, effectiveness of Tocilizumab was as-
sessed on 64 COVID-19 patients. Since other factors affect 
survival rate as well, such as patients’ comorbidities and 
the rate of demand for respiratory support, the study could 
not support effectiveness of Tocilizumab in modifying mor-
tality of COVID-19 patients with hyper inflammation in 5 
days, however, the study showed that it was effective on 
the survival of patients who stayed alive after 5 days and 
reduced the rate of mortality between days 6 and 30 on the 
second outcome, defined as incidence of invasive ventila-
tion, thrombosis and hemorrhage [9]. 
A series of controversial results were observed in another 
study. In a retrospective case control study on 45 COVID-19 
patients, 20 were treated with Tocilizumab, and 25 treated 
with standard care. Charlson comorbidity index (19 specif-
ic conditions like diabetes, MI, COPD, dementia, etc.) was 
higher than normal among Tocilizumab group, presented 
with more severe symptoms such as higher oxygen demand, 
and had poorer biological findings like severe lymphope-
nia and higher CRP level than patients without Tocilizumab 
(5.3 [±2.4] vs 3.4 [±2.6], p=0.014). However, Tocilizumab 
group accounted for less number of ICU admissions and/or 
death in comparison with the standard group. Despite the 
small sample size and the retrospective nature of the work, 
the study suggests that Tocilizumab may improve the con-
ditions of the patients with severe SARS-CoV2 pneumo-
nia [44]. In contrast, a retrospective study was performed 
among 224 patients hospitalized with COVID‐19. Tocili-
zumab was administered to two groups of 57 non ICU and 
167 ICU patients, and then the rate of fungal infections and 
in hospital mortality rates were assessed. Tocilizumab was 
administered to 28.1% of ICU patients and 4.2% of non 
ICU patients. Rate of fungal infections was significantly 
higher in patients who received Tocilizumab irrespective 
of being in ICU or non ICU group. Among the non ICU 
patients, Tocilizumab was accompanied with higher ratio of 
later ICU admission. Also in both groups, demand for inva-
sive mechanical ventilation increased, and relatively higher 
in‐hospital mortality rates were observed after Tocilizumab 
administration. Therefore Tocilizumab did not decrease in‐
hospital mortality in this cohort [45].
Effects of Tocilizumab was also assessed in a clinical trial 
among 42 COVID-19 patients in severe and critical stage. 
Severe stage is defined as chronic obstructive pulmonary 
disease and lower CRP levels, and critical status is defined 
as hypertension, diabetes, and higher CRP levels. Among 20 
patients in severe conditions, only one patient died, and out 
of 22 critical patients, 6 patients died, and in general, con-
ditions of 35 patients improved after Tocilizumab adminis-
tration. Lung images related to the patients before and after 
receiving Tocilizumab were compared, and seven patients 
showed worsening pulmonary conditions in imaging, the 
same number did not represent considerable improvement, 
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and images of the remaining 28 patients showed noticeable 
changes in favor of healing. In this study, the mortality rate 
among patients receiving Tocilizumab in severe or critical 
status was reported to be 16% with a 6% reduction from 
22% mortality rate observed in previous studies [46]. 
A retrospective analysis was done on 40 patients treated 
with Tocilizumab, most of whom had several comorbidi-
ties, and all had a series of biological abnormalities such as 
lymphopenia, increased CRP, ferritin, fibrinogen, D-dimer, 
and liver enzymes. Clinical state in 30 patients improved 
with Tocilizumab, but 10 patients died. Among the survi-
vors, CRP levels dropped sharply as early as day 4 after 
Tocilizumab administration, and reached normal levels on 
day 6. Fibrinogen and lymphocyte count also returned to 
normal on day 6. Ferritin levels decreased significantly as 
well. The death of 10 patients a few days after Tocilizumab 
administration, may suggest that the treatment was too late, 
therefore it raised the notion “window of opportunity” for 
Tocilizumab. The dramatic reduction of serum CRP levels 
were observed both in patients successfully treated with To-
cilizumab and in those who died after Tocilizumab adminis-
tration. further investigations is needed on larger groups of 
patients for a more definite result [47]. 
In a multicenter observational study, the association be-
tween Tocilizumab exposure and hospital-related mortality 
among patients requiring intensive care unit (ICU) support 
for COVID-19 was checked in 13 hospitals. Tocilizumab 
decreased hospital-related mortality in patients who had 
CRP levels higher than 15 mg/dL. Additionally, a notice-
able decline in mortality was found among patients who re-
quired mechanical ventilation and also in patients less than 
65 years of age. It could be concluded that Tocilizumab has 
a suppressing effect on inflammatory stage of COVID-19 
patients [8]. 
In another study the difference between single and multiple 
doses of Tocilizumab were compared as a single center ex-
perience. It appears that a single dose of Tocilizumab may 
have positive outcomes in critical patients even in those 
receiving glucocorticoids. Besides, repeated doses (even in 
lower doses) of Tocilizumab is also beneficial for critically 
ill patients. It is proven that repeated dosing of Tocilizumab 
at a frequency of daily, every other day, or every 3 days in 
various doses would be useful in critical patients, or even 
in patients whose IL6 levels are exceptionally high (90 
times of normal levels). Tocilizumab has a long duration of 
action and its receptors have saturable binding properties, 
therefore the dose of Tocilizumab could be reduced with 
repeated use. Tocilizumab might be effective in the preven-
tion or treatment of cytokine storms. After administration 
of Tocilizumab most patients recovered from acute phase 
and were stabilized following a later gradual fall in IL‐6 
levels [48].
A systematic review was performed on studies about treat-
ing COVID-19 patients with Tocilizumab. Total number 
of 29 patients were enrolled in these studies. IL-6 levels 
in these patients were elevated initially after Tocilizumab 
therapy which is in favor of cytokine storm and may persist 
in a number of patients which was seen among 2 of these 
patients. However, after initiation of Tocilizumab, C reac-
tive protein levels declined sharply, which shows that this 
drug is capable of reducing hyper-inflammation but due to 
the mentioned complications, further investigation is re-
quired [7]. 
Two cases of patients with COVID-19, who received Tocili-
zumab, complicated with cytokine release syndrome and its 
fatal correlate, secondary hemophagocytic lymphohistio-
cytosis (sHLH), were studied. In spite of the medication, 
they both progressed to sHLH and one of them developed 
viral myocarditis. Therefore the safety of this drug and the 
timing for its use should be taken into consideration [49]. 
Anakinra
In a retrospective cohort study, the effectiveness of Anak-
inra was evaluated among 36 COVID-19 patients with 
acute respiratory syndrome. Patients were divided into 
two groups receiving high dose and low dose of Anakinra 
and results were compared with a group of patients with 
standard treatment. Prior to study, 16 patients had received 
only mechanical ventilation and standard therapy and com-
prised the study’s control group. 29 patients formed the 
high dose Anakinra group and 7 patients received low dose 
of Anakinra. In Anakinra group, low dose of Anakinra was 
not associated with a significant difference in CRP levels 
or changes in clinical status. However, high-dose drug on 
21 patients were associated with reduction in serum CRP 
and progressive improvement in respiratory function, five 
patients required mechanical ventilation and the remain-
ing three died. Totally 90% of patients survived in the high 
dose Anakinra group and 56% in the standard treatment 
group. Rate of survival without mechanical ventilation was 
72% in the high dose Anakinra group versus 50% in the 
standard treatment group. This study showed that treatment 
with high-dose Anakinra was safe and associated with bet-
ter clinical outcomes [10]. 
A clinical trial was done on nine COVID-19 patients who 
were all older than 18 years old and their chest CT scans 
were compatible with COVID-19-pneumonia. After ini-
tiation of Anakinra, only one out of nine patients showed 
acute respiratory failure after 6 hours of drug initiation 
which demanded discontinuation of therapy. All of the oth-
er eight patients showed good clinical and biological out-
comes after three days of Anakinra administration. CRP 
levels decreased steadily during six days of therapy and 
was normalized on day 11. In all patients, an early chest CT 
scan between days 5 to 8 showed no more abnormalities. 
All nine patients were alive at the last follow-up [50]. 
The efficacy of Anakinra on preventing mechanical venti-
lation was assessed in a case series among 11 patients with 
severe COVID-19. Seven of the patients did not require 
mechanical ventilation, and all of them were discharged. 
Four patients who received Anakinra in more than 4 days 
after onset of acute hypoxemic respiratory failure required 
mechanical ventilation, three of whom were eventually ex-
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tubated (2 discharged and 1 remained hospitalized), and 1 
died. All 3 patients who were eligible for Anakinra adminis-
tration (such as documented SARS-CoV-2, fever, and ferri-
tin >1,000 ng/mL with one additional laboratory marker of 
hyper-inflammation) but did not receive the drug, required 
mechanical ventilation. Ultimately this study suggests that 
Anakinra may be a potential option in treating COVID-19 
patients with cytokine storm syndrome [51].
Effectiveness of Anakinra; an interleukin 1 inhibitor; was 
assessed in a case report study among 5 patients with he-
matological diseases, severe SARS-CoV-2 infection and 
hyper-inflammation following Tocilizumab treatment. De-
spite the previous use of Tocilizumab, all patients showed 
minimal improvement, as they needed higher oxygen aid 
with progressive elevation of inflammatory markers. Af-
ter administration of Anakinra, patients’ clinical condition 
continued to deteriorate, as predicted by progressive wors-
ening of radiology images accompanied by continuous rise 
in inflammatory markers. Moreover, an increase in IL-10, 
the most immunosuppressive cytokine, was observed af-
ter the administration of Anakinra. It seems that Anakinra 
could not improve clinical status of these patients [52]. 
The efficacy of Anakinra was studied as a sole treatment 
on a 47-year-old man with no history of smoking and no 
noticeable medical history except for well-controlled and 
untreated asthma, and possible allergy to glucocorticoids. 
He was primarily treated with hydroxychloroquine, azithro-
mycin, and oxygen but no significant change was observed 
in the patient symptoms. Following Anakinra administra-
tion, an abrupt and progressive improvement occurred in 
respiratory condition, the patient’s fever faded, clinical sta-
bilization was achieved and inflammatory parameters were 
normalized after 10 days. Also the chest x-ray at this time 
showed noticeable improvement of the pulmonary infil-
trates. Therefore this study reported a well-tolerated case 
of COVID-19 treated with Anakinra [53]. 
The effectiveness of Anakinra on a 37 year old male with 
COVID-19 was studied in a case report. The drug was start-
ed with a dose of 100 mg/day. After 7 days of treatment, 
the patient’s retrosternal chest pain was relieved, CRP and 
D-dimer values, as well as echocardiogram normalized. 
Anakinra was discontinued 7 days later and the patient was 
discharged in good clinical condition. He had no problem 
in his follow-up visit 2 weeks after the hospital discharge, 
while other treatment options like colchicine and indometh-
acin did not affect the patient’s symptoms considerably pri-
or to the administration of Anakinra. This study suggested 
that Anakinra may be effective in alleviating COVID-19 
inflammatory symptoms [54]. 
In another case report, the effect of Anakinra on a 57 year 
old man with COVID-19 was assessed for reducing in-
flammatory responses caused by the disease. The patient 
received Anakinra for 7 days along with Tocilizumab and 
a group of antibiotics. During the follow up, inflammation 
was diminished and body temperature became normal. By 
day 16, the patient faced noticeable improvement in respi-
ratory system, in which the oxygen saturation rose to 92% 
using Venturi mask, but a series of adverse reactions were 
reported following this study like elevation of procalci-
tonin, and lung consolidation which was detected on day 
10 and could probably be due to persistent viral infection 
and inflammation. Since Anakinra has a short duration of 
action, its administration could be discontinued as soon as 
adverse reactions appear, a property in contrast to long act-
ing medications such as Tocilizumab [38]. 
Canakinumab
In a prospective study, effectiveness of Canakinumab was 
evaluated among 150 Covid-19 patients, out of whom 88 
patients received Canakinumab. Patients were compared 
according to changes in oxygen support, duration of hospi-
talization, and blood factors. In 61.4% of patients, Canaki-
numab significantly decreased oxygen support requirement. 
Median range of hospitalization was 24 days in the entire 
population and 6 days following Canakinumab administra-
tion. Also a significant increase in lymphocyte count and 
decrease in CRP levels were observed among patients who 
received Canakinumab. [55]
In a study among 48 patients, effects of Canakinumab was 
assessed on hospitalization duration, survival rate, and ox-
ygen status in a clinical trial. 33 patients received Canak-
inumab and the rest received standard therapy (antivirals, 
antibiotics and Hydroxychloroquine). Median age, comor-
bidities and presenting symptoms were relatively similar 
between two groups. On day 10 after Canakinumab admin-
istration, a 63.2% decrease in supplemental oxygen was 
observed and ventilation improved significantly. Regarding 
survival rate, Canakinumab group outnumbered the stan-
dard group with 90% survival rate versus 73.3%. The hos-
pitalization rate for less than 21 days was 63% in Canaki-
numab group, whilst in the standard group all patients were 
hospitalized more than 21 days [56].
In a study 34 patients were enrolled in a clinical trial to 
observe the effectiveness of Canakinumab on ICU patients 
with Covid-19. Effectiveness of this drug was evaluated 
monitoring inflammation indices and oxygen demand. Pa-
tients were divided into two groups of 17 individuals. One 
group received Canakinumab and the other group received 
the standard therapy for Covid-19 (Hydroxychloroquine 
or Lopinavir/Ritonavir). The groups were observed on day 
zero (before drug administration), day 3 and day 7 of drug 
administration. Inflammation indices such as D-dimer and 
fibrinogen dropped significantly, P/F (arterial pO2 divided 
by the FIO2) ratio increased, and oxygen flow decreased 
in Canakinumab group on day 3 and 7 versus day zero. On 
the other hand, supply of oxygen increased in the standard 
group on day 3 versus day zero, but decreased in day 7 
versus day zero. Another finding was the reduction in the 
lactate levels in Canakinumab group which is a solid sign 
of reduced respiratory fatigue in this group of patients.[57]
Effects of Canakinumab was evaluated among ten hospi-
talized COVID-19 patients as a clinical trial and the results 
were compared with another ten hospitalized COVID-19 
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patients who did not receive this drug. There were no re-
corded adverse reactions such as site injection reactions. 
Following its administration, serum CRP was decreased 
rapidly and lung oxygenation improved. 45 days after hos-
pitalization, all ten patients in Canakinumab group were 
discharged from the hospital with no need for oxygen or 
physical complications related to COVID-19 and no neu-
tropenia or bacterial sepsis was seen. By contrast, the pa-
tients on the control group had slower improvements in se-
rum CRP and oxygenation. After 45 days of hospitalization, 
in non-Canakinumab group, one patient deceased and the 
others were discharged, among whom one patient required 
oxygen therapy [58].
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